Neurology Advisor1d
Switch to Cladribine From Natalizumab Maintains Disease Stability in Relapsing MS
In patients with relapsing MS, the transition to cladribine from natalizumab is a safe and effective option that provides sustained disease stability.
BMJ2d
Multiple sclerosis: Investigation into side effects of switching patients to natalizumab biosimilar
A London hospital is to investigate why over half of its patients with multiple sclerosis (MS) who switched from disease modifying therapy Tysabri (natalizumab) to biosimilar Tyruko have had to be ...
Medpage Today on MSN3d
Trump Team Fires Alzheimer's Staff; Herpesvirus and Alzheimer's; MS Drug Switches
Among those fired in the recent spate of Trump administration cuts are staff members at the NIH's Center for Alzheimer's and ...
NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects
A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc’s (NASDAQ:BIIB) Tysabri ...